These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 995040)

  • 1. [Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].
    Mies R
    Med Klin; 1976 Nov; 71(46):2013-6. PubMed ID: 995040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM; Howard AN
    Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical trial with a nonamphetaminic anoretic].
    Campagnoli M
    Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
    Riesco J; Troncoso G; Costamaillere L; Rodríguez J
    Rev Med Chil; 1977 Jun; 105(6):375-9. PubMed ID: 331428
    [No Abstract]   [Full Text] [Related]  

  • 7. A double blind controlled trial of a new anorectic agent AN448.
    Woodhouse SP; Nye ER; Anderson K; Rawlings J
    N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of obesity with mazindol (author's transl)].
    Escher M
    Schweiz Rundsch Med Prax; 1976 Jun; 65(24):751-4. PubMed ID: 981189
    [No Abstract]   [Full Text] [Related]  

  • 9. [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].
    Gołebiowska M; Chlebna-Sokoł D; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(2):311-4. PubMed ID: 7017826
    [No Abstract]   [Full Text] [Related]  

  • 10. A multi-centre general practice trial of mazindol in the treatment of obesity.
    Maclay WP; Wallace MG
    Practitioner; 1977 Mar; 218(1305):431-4. PubMed ID: 322112
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical use of mazindol in the treatment of essential obesity].
    Guazzelli R; Piazzini M; Conti C; Papi L; Strazzulla G; Matassi L
    Clin Ter; 1987 Mar; 120(5):385-91. PubMed ID: 2953538
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mazindol in the treatment of obesity in diabetics (author's transl)].
    Felt V; Nedvídková J
    Cas Lek Cesk; 1977 Sep; 116(39):1214-7. PubMed ID: 922789
    [No Abstract]   [Full Text] [Related]  

  • 13. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial.
    Atkinson RL; Greenway FL; Bray GA; Dahms WT; Molitch ME; Hamilton K; Rodin J
    Int J Obes; 1977; 1(2):113-20. PubMed ID: 363629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mazindol (AN-448): a new non-amphetamine anorectic in the treatment of exogenous obesity].
    Delitala G; Alagna S; Masala A
    Clin Ter; 1977 Jun; 81(6):547-54. PubMed ID: 884939
    [No Abstract]   [Full Text] [Related]  

  • 16. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 17. Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women.
    Yoshida T; Sakane N; Umekawa T; Yoshioka K; Kondo M; Wakabayashi Y
    Int J Clin Pharmacol Res; 1994; 14(4):125-32. PubMed ID: 7607785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre study comparing mazindol and placebo in obese patients.
    Walker BR; Ballard IM; Gold JA
    J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity.
    Defelice EA; Chaykin LB; Cohen A
    Curr Ther Res Clin Exp; 1973 Jul; 15(7):358-66. PubMed ID: 4198296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.